Michael Birrer, MD, PhD | Authors


Historical and Current Data Inform the Ovarian Treatment Landscape for Practicing Oncologists

February 21, 2021

Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.

Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer

March 25, 2018

Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.

Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer

June 04, 2017

Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer.

Current and Emerging Roles of PARP Inhibition in Ovarian Cancer

December 08, 2016

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.